Trials / Recruiting
RecruitingNCT04791358
Decision Impact Trial of KidneyIntelX
A Prospective Decision Impact Trial of KidneyIntelX in Patients With Type 2 Diabetes and Existing Chronic Kidney Disease
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,500 (estimated)
- Sponsor
- Renalytix AI, Inc. · Industry
- Sex
- All
- Age
- 23 Years
- Healthy volunteers
- Not accepted
Summary
The current trial is designed to evaluate how the results of KidneyIntelX test impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | KidneyIntelX | KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function and kidney failure in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g). |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2024-11-01
- Completion
- 2024-12-01
- First posted
- 2021-03-10
- Last updated
- 2024-04-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04791358. Inclusion in this directory is not an endorsement.